News
-
Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement
NEW YORK and SOUTH SAN FRANCISCO, Calif., June 13, 2022 /PRNewswire/ — Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced […]
-
Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination
Extraordinary General Meeting of BAC’s shareholders postponed until June 3, 2022, at 10:00 a.m., Eastern Time NEW YORK and SOUTH SAN FRANCISCO, May 31, 2022 /PRNewswire/ — Biotech Acquisition Company (NASDAQ: BIOT) (“BAC“), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, […]
-
Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC’s Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity Facility
Extraordinary General Meeting of BAC’s shareholders is scheduled for June 1, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed “Blade Biotherapeutics, Inc.” upon Business Combination closing, with common stock and warrants expected to trade on the Nasdaq Global Market under ticker symbols “BBTX” and “BBTXW” Post-closing company has secured […]
-
Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
NEW YORK, April 4, 2022 – Biotech Acquisition Company (NASDAQ: BIOT) (“BAC“), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, the first amendment to its registration statement on Form S-4, filed on March 15, 2022 (as […]
-
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
U.S. Food and Drug Administration (FDA) provides feedback necessary to proceed into a phase 2 proof of concept (PoC)/dose ranging study of cudetaxestat in patients with idiopathic pulmonary fibrosis (IPF) Company plans to advance cudetaxestat, a non-competitive inhibitor of autotaxin, into a 26-week phase 2 clinical trial in the second […]
-
Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
New York, NY, March 16, 2022 – Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, a registration statement on Form S-4 relating to its previously announced proposed […]
-
Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
New York, NY, January 3, 2022 – Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential submission to the United States Securities and Exchange Commission (“SEC”), for receipt by the SEC on December […]
-
Biotech Acquisition Company and Blade Therapeutics Announce Definitive Merger Agreement
NEW YORK and SOUTH SAN FRANCISCO, Calif., November 3, 2021 – Biotech Acquisition Company (Nasdaq: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., announced today that they have entered into a definitive merger agreement…
-
Biotech Acquisition Company Announces Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 18, 2021
Biotech Acquisition Company (NASDAQ: BIOTU) (the “Company”) announced that, commencing March 18, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares (“Class A Ordinary Shares”) and warrants included in the units. No fractional warrants will be issued upon separation of the units and only…
-
Biotech Acquisition Company Announces Closing of $230,000,000 Initial Public Offering.
Biotech Acquisition Company (the “Company”) announced today that it has closed its initial public offering of 23,000,000 units, including 3,000,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000…
Filings
Cautionary Note Concerning Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements,” including with respect to the anticipated use of the net proceeds from the Company’s initial public offering. No assurance can be given that the net proceeds will be used as indicated. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s prospectus relating to the offering, which is filed with the U.S. Securities and Exchange Commission (“SEC”). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update its forward-looking statements, except as required by law.
No Offer or Solicitation
The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act of 1933, as amended.